profile icon
Prof

Simon Harrison

Honorary
The Sir Peter Maccallum Department of Oncology
Multiple Myeloma
Cellular Immunotherapy
Science and Technology
Clinical Apheresis
CAR-T
Haematology
Male
Felmale
Adult
Simon Harrison's Profile Picture
Prof

Simon Harrison

 
Division
Medicine, Dentistry and Health Sciences
 
Primary Interest
Immunotherapy of Multiple myeloma
Simon Harrison's Profile Picture
Prof

Simon Harrison

 
Print
Simon's  Short Profile
 

Find out more about Simon Harrison's experience

Simon Harrison's highlights

Projects

Displaying the 9 most recent projects from 9 for Simon Harrison.

Project icon

More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patientreported outcome measures: the MY-PROMPT-2 trial

2022 - 2027
Active
Project icon

Adjuvant immunotherapy to improve the efficacy, durability, and cost effectiveness of CAR T-Cell therapy for aggressive lymphoma

2022 - 2026
Active
Project icon

Studying the origins, maintenance and resistance mechanisms of poor risk paediatric leukaemia at single cell resolution to develop novel therapeutic approaches

2021 - 2025
Active
Project icon

PhD research project: The epidemiology of multiple myeloma (MM)

2020 - 2023
Completed
Project icon

ProTreat: an adaptive and rapid implementation trial of novel therapies to prevent and treat COVID19 infection in high risk cancer patients

2020 - 2022
Completed
Project icon

ASSESSING CAR T CELL THERAPY IN MURINE MULTIPLE MYELOMA MODELS

2017 - 2018
Completed
Project icon

GENE MODIFIED T CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR FOR A KAPPA LIGHT CHAIN ANTIGEN TO TREAT MULTIPLE MYELOMA

2016 - 2017
Completed
Project icon

NOVEL APPROACHES TO TREAT REFRACTORY HAEMATOLOGICAL MALIGNANCIES

2015 - 2017
Completed
Project icon

A NEW APPROACH TO TARGETING CELL GROWTH FOR THE TREATMENT OF CANCER

We have made the fundamental discovery that ribosomal gene transcription is not simply a 'house keeping' process in cancer cells but is requ..

2012 - 2014
Completed

9

Projects

Project Types

7

Research Grant

2

Research Contracts

Scholarly Works

Displaying the 10 most recent scholarly works from 269 for Simon Harrison.

Scholarly works icon

Infectious complications of bispecific antibody therapy in patients with multiple myeloma.

Beatrice Z Sim, Anthony Longhitano, Jeremy Er, Simon J Harrison, Monica A Slavin, Benjamin W Teh

Journal article  |  2023  |  Blood Cancer J

Scholarly works icon

Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma.

Torben Plesner, Simon J Harrison, Hang Quach, Cindy Lee, Adam Bryant, Annette Vangsted, Jane Estell, Michel Delforge, Fritz Offner, Patrick Twomey, Voleak Choeurng, Junyi Li, Robert Hendricks, Shannon M Ruppert, Teiko Sumiyoshi, Karen Miller, Eunpi Cho, Fredrik Schjesvold

Journal article  |  2023  |  Clin Hematol Int

INTRODUCTION: This phase 1 trial assessed the safety, pharmacokinetics, and preliminary antitumor activity of RO7297089, an anti-B..

Scholarly works icon

The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells.

Kelden Richardson, Simon P Keam, Joe Jiang Zhu, Deborah Meyran, Criselle D'Souza, Sean Macdonald, Kerry Campbell, Michael Robbins, Natalie A Bezman, Kirsten Todd, Hang Quach, David S Ritchie, Simon J Harrison, H Miles Prince, Joseph A Trapani, Misty R Jenkins, Paul A Beavis, Phillip K Darcy, Paul J Neeson

Journal article  |  2023  |  Haematologica

Patients with refractory relapsed multiple myeloma respond to combination treatment with elotuzumab and lenalidomide. The mechanis..

Scholarly works icon

Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax

David Sharon, Fengjiao Dunbar, Paul Jung, Xifeng Wang, Xiaotong Li, Christine Mantis, Orlando F Bueno, Cyrille Touzeau, Philippe Moreau, Simon J Harrison, Luciano J Costa, Jonathan L Kaufman, Nizar J Bahlis, Shaji K Kumar, Jeremy A Ross, PK Epling-Burnette

Journal article  |  2022  |  Blood

Scholarly works icon

Infectious Complications of Bispecific Antibody Therapy in Patients with Multiple Myeloma

Beatrice Z Sim, Anthony Longhitano, Jeremy Er, Simon J Harrison, Monica Slavin, Benjamin W Teh

Journal article  |  2022  |  Blood

Scholarly works icon

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

Alexander M Lesokhin, Joshua Richter, Suzanne Trudel, Adam D Cohen, Andrew Spencer, Peter A Forsberg, Jacob P Laubach, Sheeba K Thomas, Nizar J Bahlis, Luciano J Costa, Paula Rodriguez Otero, Maria-Victoria Mateos, Jesus G Berdeja, Rayan Kaedbey, Amrita Y Krishnan, Rafael Fonseca, Voleak Choeurng, James Cooper, Teiko Sumiyoshi, Chihunt Wong, et al.

Journal article  |  2022  |  Blood

Scholarly works icon

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L Kaufman, Hang Quach, Rachid C Baz, Annette Juul Vangsted, Shir-Jing Ho, Simon J Harrison, Torben Plesner, Philippe Moreau, Simon D Gibbs, Eva Medvedova, Muhammad Jalaluddin, Jeremy A Ross, Leanne Lash Fleming, Yan Luo, Nizar Jacques Bahlis

Journal article  |  2022  |  Blood

Scholarly works icon

Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity

Suzanne Trudel, Nizar J Bahlis, Andrew Spencer, Rayan Kaedbey, Paula Rodriguez Otero, Simon J Harrison, Chihunt Wong, Grant R Goodman, Rin Nakamura, Voleak Choeurng, James Cooper, Maria-Victoria Mateos

Journal article  |  2022  |  Blood

Scholarly works icon

Real-world utility of early measurable residual disease assessments by multi-parametric flow cytometry in adult patients with B-lymphoblastic leukemia receiving Hyper-CVAD induction chemotherapy

Rithin Nedumannil, David Ritchie, Ashish Bajel, Ashley P Ng, Simon J Harrison, David Westerman

Journal article  |  2022  |  EUROPEAN JOURNAL OF HAEMATOLOGY

Multi-parametric flow cytometry (MFC) has a well-established role in measurable residual disease (MRD) monitoring in patients with..

Scholarly works icon

The second revision of the International Staging System (R2-ISS) stratifies progression-free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population

Joanne LC Tan, Cameron Wellard, Elizabeth M Moore, Peter Mollee, Rajeev Rajagopal, Hang Quach, Simon James Harrison, Emma-Jane McDonald, P Joy Ho, H Miles Prince, Bradley M Augustson, Philip Campbell, Zoe K McQuilten, Erica M Wood, Andrew Spencer

Journal article  |  2022  |  BRITISH JOURNAL OF HAEMATOLOGY

269

Scholarly Works

Keyword Analysis

Oncology and Carcinogenesis
Clinical Health
Clinical Sciences
Cardiovascular Medicine and Haematology
Expanding Knowledge
Immunology
Public Health (excl. Specific Population Health)
Medical Biochemistry and Metabolomics
Neurosciences
Pharmacology and Pharmaceutical Sciences

Credentials

Positions

Honorary

The Sir Peter Maccallum Department of Oncology

Honorary

Medicine - St Vincent's Hospital

Chair

-Myeloma Scientific & Advisory Group (MSAG)

Education

Fellow Post Graduate Specialist training in Adult medicine

The Royal Australian College of Physicians

Doctor of Philosophy

University Of Glasgow

Fellow The Royal College Of Pathologists UK

Royal College Of Pathologist London

Member The Royal College of Physicians

Royal College Of Physicians London

Links